Brad Bolzon

Investor

Chairman, Managing Director at Versant Ventures

Canada

Writes $100K – $5M checks · typically $1.5M

About

Brad Bolzon merges 13 years of senior R&D and business development at Eli Lilly and Roche with architecting cross-border company creation—co-founding Inception Sciences, chairing CRISPR Therapeutics, and building multi-hub presence.

Invests in

BiotechHealthtechMedical Devices

Deals · 2

Turnstone BiologicsBoard seat

via Versant Ventures · filed Jan 2019 · $42.1M raise

Aset TherapeuticsBoard seat

via Versant Ventures · filed Jan 2018 · $12.1M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Alex Mayweg

Managing Director at Versant Ventures

Alicia Levey

Venture Partner at Versant Ventures

Andrew Jefferson

Operating Partner at Versant Ventures

Ariel Kantor

Principal at Versant Ventures

Barbara Lubash

Managing Director at Versant Ventures

Beckie Robertson

Managing Director at Versant Ventures

Bill Link

Investor at Versant Ventures

Brian Atwood

Managing Director at Versant Ventures

Network9

Alex Mayweg

Managing Director at Versant Ventures

Barbara Lubash

Managing Director at Versant Ventures

Beckie Robertson

Managing Director at Versant Ventures

Bill Link

Investor at Versant Ventures

Brian Atwood

Managing Director at Versant Ventures

Carlo Rizzuto

Managing Director at Versant Ventures

Clare Ozawa

Managing Director at Versant Ventures

Don Milder

Managing Partner at Versant Ventures

Erik T. Engelson

Venture Partner at Versant Ventures

Investors connected to Brad in public investor directories — a warm-intro map.